Zentalis Pharmaceuticals Inc (ZNTL) Hedge Fund & Institutional Holdings (Q2 2026)

ZNTL ranks #4250 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

ZNTL is a disclosed holding of Two Sigma (Two Sigma Investments), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

ZNTL is a top-conviction position for 5AM Venture Management, LLC — at 6.7% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in ZNTL belongs to Squadron Capital Management LLC, but the position matters far more to 5AM Venture Management, LLC, who has 6.7% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

ZNTL is down 4.9% today, but institutions show net buying of $29.3M this quarter — a divergence between today's price move and the underlying institutional flow.

ZNTL reported a net loss of $139.5M over the trailing twelve months.

• Not yet profitable — net loss of $139.5M over the trailing twelve months
• Revenue declined 100.0% year over year
• Net income improved year over year, from -$162.8M to -$139.5M
• Operating cash flow was negative, using $125.2M in cash
• Current ratio of 6.93x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.34x equity — within a conventional range